leisure time -WSS

leisure time

author：focus 2025-09-29 18:17:10 - browse：983

David Sabatini at home — David Sabatini posed at his home in Cambridge in 2022. Craig F. Walker/Boston Globe

Former MIT and Whitehead Institute star biologist David Sabatini, who lost his lofty positions after being accused of violating sexual harassment policies in 2021, is rejoining the Boston scientific community as head of a research group at a new laboratory under the umbrella of a Czech-based scientific institute.

Sabatini, who has denied harassing anyone and filed litigation over the claims, has been working since last October in a senior research position at the Institute of Organic Chemistry and Biochemistry, in the Czech Republic capital of Prague, investigating scientific questions in the areas of cell growth and metabolism, similar to his past research at Whitehead.

The Czech institute, known as IOCB Prague, is realizing a long-held ambition to expand into the Boston biotech hub, confirmed the institute’s director, Jan Konvalinka.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Tori Bowie and the unacceptable rates of Black maternal death
Next article： Positive childhood experiences can help future health

Wikipedia

WSS

Leading voice in opioid treatment defends methadone clinic system

App could help diagnose ear infections more accurately — and at home

General Catalyst, Summa Health deal will turn on physician buy

Cognito secures funding to test medical device for Alzheimer's

I was wrong about Geron's blood cancer drug. Now, is it a takeover target?

Intermittent fasting comes with a heart risk? Not so fast

entertainment

leisure time

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

explore

Wildfire smoke exposes gaps in outdoor worker protections

Asbestos, a deadly carcinogen, banned by EPA

Moonlake's readout produced a cash windfall. Risks remain

Neuroscience’s long legacy of racism

Wildfire smoke exposes gaps in outdoor worker protections

FDA drug safety: Singulair case shows systemic surveillance flaws

Hollywood unions extend contract negotiations for actors

AstraZeneca to buy developer of next

Medicare proposal to cover medical devices draws a mixed reaction

ARCH Venture Partners is raising $3 billion for a life sciences fund

entertainment

Quicker fix for pulse oximeters urged during FDA public meeting

U.K. researchers warn about biases in medical devices, algorithms

Vertigo drug brings hope for rare neuron disorder, Niemann

Vertex non

Virtual Event: March of the Biosimilars

General Catalyst, Summa Health deal will turn on physician buy

Wikipedia

focus

focus

knowledge